Japanese biotech Nxera Pharma (TSE: 4565) has revealed that Germany’s Boehringer Ingelheim opted not to exercise its ...

Danish clinical-stage techbio Evaxion today revealed it has been informed that MSD (tradename of Merck & Co outside the USA ...

The US president has signed an Executive Order directing federal agencies to move more quickly toward rescheduling marijuana ...

US radioisotope producer Niowave has expanded its supply agreement with British pharma AstraZeneca (LSE: AZN) to a 10-year ...

Orum Therapeutics, a Korea-listed biotech developing degrader-antibody conjugates (DACs), has secured 145 billion South ...

Iceland-based biosimilars developer Alvotech and a US affiliate of Israel’s Teva Pharmaceutical Industries, today announced ...

Syremis Therapeutics, a Tel Aviv, Israel, and Boston, USA-based clinical-stage biopharma developing novel medicines to make a ...

The USA’s Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational ...

US precision allosteric therapeutics company Atavistik Bio has raised a $120 million Series B financing.

Shares of Amicus Therapeutics shot up 30% to $10.89 in pre-market activity today, on the news of a takeover offer from fellow USA-based BioMarin.

South Korean biosimilars specialist Celltrion said the European medicines regulator has adopted a positive opinion for an autoinjector version of SteQeyma, its biosimilar to Stelara (ustekinumab).

Danish pharma major Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide and semaglutide) injection, to be used ...